Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease
Titel:
Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease
Auteur:
Donohue, James F. Kerwin, Edward Sethi, Sanjay Haumann, Brett Pendyala, Srikanth Dean, Lorna Barnes, Chris N. Moran, Edmund J. Crater, Glenn